Calistoga Drug Shrinks Tumors in Lab Studies
Luke Timmerman12/9/08
Seattle-based Calistoga Pharmaceuticals said that its lead experimental drug, CAL-101, killed cancer cells in lab studies of multiple blood malignancies. The drug is designed to block a marker inside cells called the PI3 kinase pathway, that is thought to play a key role in tumor cell growth, survival, and migration. The findings were delivered in an oral presentation at the American Society of Hematology meeting in San Francisco.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
Calistoga Pharmaceuticals « Ask Lazlo
12/16/08 3:04 pm
[...] News: Lead drug CAL-101 is said to kill tumor cells (Dec. 9, 2008) [...]
Cell pathway on overdrive prevents normal cancer response to dietary restriction | Pharma Strategy Blog
10/26/10 5:24 pm
[...] Calistoga Drug Shrinks Tumors in Lab Studies (xconomy.com) This entry was posted in Cancer, Mechanism of Action, New products, Pipeline, Science, Targeted Therapies, Technology and tagged competitive intelligence, forecasting portfolio analysis, M&A due diligence, oncology cancer, pharmaceutical biotechnology marketing strategy. Bookmark the permalink. ← MicroRNA-based Diagnostic Identifies Squamous Lung Cancer With 96% Sensitivity Herceptin proven to benefit women with HER2 positive early breast cancer → blog comments powered by Disqus /* * * * * */ [...]